Ann: Capital Raising Presentation, page-77

A commercialisation vehicle has to be able to sell indications as potential revenue streams or fund them through to full commercial development themselves.

It doesn't make sense to talk of 5K treatments (for DFU) in some pro-forma income projection many years (MST report) out unless that is credible against the competition your product will have then.

A big toe might be amputated for critical limb (well a toe isn't a limb - but there is vascularisation - blood vessels) ischemia perhaps rather than a through the skin wound - I don't know - its just a possibility.

I think you did use the word 'significant'. But what we actually need is statistical significance. And from memory I think 6 samples is about as few as is possible to do that with - students t tests and the like. But I'm willing to be corrected.

I looked for CYP and MSB in a recent list of stocks that Commsec was willing to grant margin loans against using the shares themselves - neither were there. Polynovo was. I don't hold Polynovo. I don't care about the market caps - I care about the competitive positions of products and I compare how recruiting is done by one company for DFU versus how it is done by another when both are in the same world.

CYP used to be, I'm pretty sure - a share that could have been used as security in a margin loan situation. The directors have altered the value in CYP shares and MSB shares it seems such that banks like commsec won't take them as securities in margin loans.

To take up new shares in Cynata a shareholder has to go outside their shareholding to get credit - unless they sell shares they hold and buy them back and pick up a possible option in the exchange (which might be a way to mitigate damage - but you don't know you'll get the full allocation if you do that) but at the cost of the brokerage.